Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model

Gene Therapy

Volumn 5, Issue 5, 1998, Pages 605-613

  Li, Z ^a   Rakkar, A ^a   Katayose, Y ^a   Kim, M ^a   Shanmugam, N ^a   Srivastava, S ^b   Moul, J W ^b   McLeod, D G ^b   Cowan, K H ^a   Seth, P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Adenovirus; Apoptosis; Bystander effect; Gene therapy; p53

Indexed keywords

BETA GALACTOSIDASE; NEUTRALIZING ANTIBODY; PROTEIN P21; PROTEIN P53;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; IMMUNOCOMPETENCE; MARKER GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA;

EID: 7144257862     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300636     Document Type: Article

References (36)

1. Nigro JM et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-708.
2. Takahashi T et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246: 491-494.
3. Baker SJ et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249: 912-915.
4. Casey G et al. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 1991; 6: 1791-1797.
5. Yonish-Rouach E et al. The role of p53 as a transcription factor in the induction of apoptosis. Behring Inst Mitt 1996; 97: 60-71.
6. Katayose D et al. Cytotoxic effects of adenovirus-mediated wild- type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res 1995; 1: 889-897.
7. Srivastava S et al. Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. Urology 1995; 46: 843-848.
8. Seth P et al. Adenovirus-mediated gene transfer to human breast tumor cells: an approach for cancer gene therapy and bone marrow purging. Cancer Res 1996; 56: 1346-1351.
9. Katayose D, Wersto R, Cowan KH, Seth P. Effects of a recombinant adenovirus expressing WAF1/Cip1 on cell growth, cell cycle, and apoptosis. Cell Growth Differ 1995; 6: 1207-1212.
10. Bates S, Vousden KH. p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev 1996; 6: 12-18.
11. Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta 1996; 1287: 77-102.
12. Ko LJ, Prives C. p53. puzzle and paradigm. Genes Dev 1996; 10: 1054-1072.
13. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
14. Carbone DP, Minna JD. In vivo gene therapy of human lung cancer using wild-type p53 delivered by retrovirus. J Natl Cancer Inst 1994; 86: 1437-1438.
15. Habib NA et al. Preliminary report: the short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Cancer Detect Prev 1996; 20: 103-107.
16. Liu TJ et al. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994; 54: 3662-3667.
17. Kock H et al. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int J Cancer 1996; 67: 808-815.
18. Clayman GL et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995; 55: 1-6.
19. Santoso JT et al. Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol Oncol 1995; 59: 171-178.
20. Bookstein R et al. p53 Gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer. Semin Oncol 1996; 23: 66-77.
21. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Adenovirus-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 1996; 12: 1617-1623.
22. Spitz FR et al. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res 1996; 16: 3415-3422.
23. Asgari K et al. Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. Int J Cancer 1997; 71: 377-382.
24. Shenk T. Adenoviridae: the viruses and their replication. In: Fields BN et al (eds). Virology, Third edn. Lippincort-Raven: Philadelphia, 1996, pp 2111-2148.
25. Morral N et al. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild-type and E2a deleted vectors. Hum Gene Ther 1997; 8: 1275-1286.
26. Dai Y et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
27. Yang Y, Su Q, Wilson JM. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol 1996; 70: 7209-7212.
28. Freeman SM et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
29. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-1584.
30. Van Meir EG et al. Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nat Genet 1994; 8: 171-176.
31. Xu M et al. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Hum Gene Ther 1997; 8: 177-185.
32. Chen HL, Carbone DP. p53 as a target for anti-cancer immunotherapy. Mol Med Today 1997; 3: 160-167.
33. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med 1996; 2: 545-550.
34. Roth J et al. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal rumor cell challenge. Proc Natl Acad Sci USA 1996; 93: 4781-786.
35. Craig C, Kim M, Li Z, Seth P. A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin- Cdk activity in human breast cancer cells. Oncogene 1997; 14: 2283-2289.
36. Li Z et al. Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther 1997, 4: 113-117.